文献速递胸部肿瘤

原发EGFR T790M突变NSCLC对三代EGFR TKI的获得性耐药机制

Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFRT790M-Mutant NSCLC.
PubMed 文献 · J Thorac Oncol · 2021-07-06

该研究分析了4例原发EGFR T790M突变NSCLC患者接受三代EGFR TKI治疗前后的肿瘤和血浆样本,鉴定出MTOR L1433S、EGFR C797S/L798I顺式突变、MET扩增和EGFR C797S等获得性耐药机制。MTOR L1433S通过AKT信号激活导致奥希替尼耐药,联合mTOR抑制剂可逆转耐药。

要点

  • 原发EGFR T790M突变NSCLC对三代EGFR TKI的获得性耐药机制包括MTOR L1433S、EGFR C797S/L798I、MET扩增和EGFR C797S。
  • MTOR L1433S通过AKT信号激活介导奥希替尼耐药,联合mTOR抑制剂可克服耐药。
  • EGFR C797S/L798I顺式突变是三代EGFR TKI的获得性耐药机制之一。

核心结论

  • 旁路激活和EGFR C797S或EGFR C797S/L798I突变是原发EGFR T790M突变NSCLC患者对三代EGFR TKI的获得性耐药机制。
  • MTOR L1433S和EGFR L858R/T790M突变NSCLC细胞对奥希替尼联合mTOR抑制剂敏感。

研究设计与样本

  • 对4例原发EGFR T790M突变NSCLC患者三代EGFR TKI治疗前后的肿瘤和血浆样本进行分析。
  • 采用全外显子测序、靶向测序、荧光原位杂交和微滴数字PCR分析遗传变异。
  • 使用Ba/F3系统确认MTOR L1433S的致癌性,并用CRISPR/Cas9-RNP在H1975细胞系中重现。

主要发现

  • 7例原发EGFR T790M/L858R突变NSCLC患者中,4例(LC1-4)接受三代EGFR TKI达到部分缓解后出现获得性耐药,中位时间27个月(范围17-48个月)。
  • 鉴定出MTOR L1433S和EGFR C797S/L798I顺式突变、MET扩增和EGFR C797S突变作为获得性耐药机制。
  • MTOR L1433S在Ba/F3模型中具有致癌性,在CRISPR/Cas9编辑的NCI-H1975细胞中通过AKT信号激活导致奥希替尼耐药(半数抑制浓度800±67 nM)。
  • 奥希替尼联合mTOR抑制剂可消除对奥希替尼的获得性耐药。

临床怎么用

  • 对原发EGFR T790M突变NSCLC患者接受三代EGFR TKI耐药后,应检测MTOR L1433S、EGFR C797S/L798I、MET扩增和EGFR C797S等耐药机制。
  • 检测到MTOR L1433S突变时,可考虑奥希替尼联合mTOR抑制剂作为克服耐药的策略。

局限性

  • 研究仅基于4例患者,样本量小。
  • 耐药机制的普遍性需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: EGFRT790M mostly exists subclonally and is acquired as the most common mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs). Nevertheless, because de novo EGFRT790M-mutant NSCLC is rare, little is known on acquired resistance mechanisms to third-generation EGFR TKIs. METHODS: Acquired resistance mechanisms were analyzed using tumor and plasma samples before and after third-generation EGFR TKI treatment in four patients with de novo EGFRT790M-mutant NSCLC. Genetic alterations were analyzed by whole-exome sequencing, targeted sequencing, fluorescence in situ hybridization, and droplet digital PCR. MTORL1433S, confirmed for oncogenicity using the Ba/F3 system, was reproduced in H1975 cell lines using CRISPR/Cas9-RNP. RESULTS: Of seven patients with NSCLC with de novo EGFRT790M/L858R mutation, four (LC1-4) who received third-generation EGFR TKIs acquired resistance after achieving a partial response (median = 27 mo, range: 17-48 mo). Novel MTORL1433S and EGFRC797S/L798I mutations in cis, MET amplification, and EGFRC797S mutation were identified as acquired resistance mechanisms to third-generation EGFR TKIs. The MTORL1433S mutation was oncogenic in Ba/F3 models and revealed resistance to osimertinib through AKT signaling activation in NCI-H1975 cells harboring the MTORL1433S mutation edited by CRISPR/Cas9 (half-maximal inhibitory concentration, 800 ± 67 nM). Osimertinib in combination with mTOR inhibitors abrogated acquired resistance to osimertinib. CONCLUSIONS: Activation of bypass pathways and the EGFRC797S or EGFRC797S/L798I mutation were identified as acquired resistance mechanisms to third-generation EGFR TKIs in patients with NSCLC with de novo EGFRT790M mutation. In addition, MTORL1433S- and EGFRL858R/T790M-mutant NSCLC cells were sensitive to osimertinib plus mTOR inhibitors.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Park HR, Kim TM, Lee Y, et al. Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFRT790M-Mutant NSCLC. J Thorac Oncol. 2021. PMID: 34242789. doi:10.1016/j.jtho.2021.06.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。